Efficacy
EVENT
At data cut-off, 24 patients (55.8%) in the Xe1000 + En160 arm had experienced a PFS event versus 29 patients (67.4%) in the En160 arm. Investigator-assessed median PFS was 7.4 months in the Xe1000 + En160 arm and 6.2 months in the En160 arm (HR 0.98, [95% CI 0.57–1.70]; Fig. 